Ranbaxy Laboratories fell 1.06% to Rs 464.50 at 15:30 IST on BSE after the company reported a consolidated net loss of Rs 73.65 crore in the quarter ended March 2014, compared with net profit of Rs 125.75 crore in the quarter ended March 2013.
Meanwhile, the BSE Sensex was up 580.80 points, or 2.60%, to 22,924.84.
On BSE, so far 4.16 lakh shares were traded in the counter, compared with an average volume of 4.61 lakh shares in the past one quarter.
The stock hit a high of Rs 472 and a low of Rs 458.50 so far during the day. The stock hit a 52-week high of Rs 505 on 7 April 2014. The stock hit a 52-week low of Rs 253.95 on 2 August 2013.
The stock had outperformed the market over the past one month till 8 May 2014, rising 5.46% compared with no change in the Sensex. The scrip had also outperformed the market in past one quarter, rising 37.91% as against Sensex's 9.66% rise.
The large-cap company has an equity capital of Rs 211.90 crore. Face value per share is Rs 5.
More From This Section
On a consolidated basis, Ranbaxy Laboratories' total income fell 1.73% to Rs 2490.51 in the quarter ended March 2014 over the quarter ended March 2013.
Ranbaxy posted a net loss of Rs 1085.25 crore on total income of Rs 13451.31 crore in the 15 months ended 31 March 2014.
The company has changed its financial year from January - December to April - March effective 1 April 2014. In view of this, the current financial year is for a period of 15 months i.e. 1 January 2013 to 31 March 2014 and, accordingly, the figures for the fifteen months ended 31 March 2014 are not comparable with the figures for the year ended 31 December 2012.
Commenting on the business results for the Quarter, Mr. Arun Sawhney, CEO & Managing Director, Ranbaxy, said, "Despite multiple challenges, Ranbaxy met its sales guidance and continued to build on its strengths. At the same time we continue to work closely with the regulatory agencies to address their concerns."
Branded and OTC category contributed Rs 1320 crore accounting for 54% of total sales during the Quarter. Generics including API category recorded Rs 1120 crore of sales for the company during the Quarter
In North America, sales for the quarter were Rs 840 crore, a growth of 13% over the corresponding quarter. The region recorded sales of Rs 4200 crore for the 15 months period ended March 2014, reflecting a strong base business growth over the corresponding period
In the USA sales for the quarter were Rs 770 crore, a growth of 19% over the corresponding quarter previous year. Sales were Rs 3750 crore for the 15 months period ended March 2014.
In the domestic market, sales for the Quarter were Rs 550 crore.
The East Europe & CIS region recorded sales of Rs 380 crore. Sales for the 15 months period ended March 2014 were Rs 2000 crore.
West Europe sales for the quarter were Rs 250 crore. Sales for the 15 months period ended March 2014 were Rs 1080 crore.
Africa and Middle East sales for the quarter were Rs 200 crore. Sales for the 15 months period ended March 2014 were Rs 1300 crore.
Asia Pacific and LATAM (including Sri Lanka) sales for the quarter were Rs 150 crore. Sales for the 15 months period ended March 2014 were Rs 920 crore.
APl business and others contribute sales of Rs 60 crore. Sales for the 15 months period ended March 2014 were Rs 750 crore.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
Powered by Capital Market - Live News